Citations

Clear

3942 citation(s) found for "To, Van".

Analysis of time‐to‐event for observational studies: Guidance to the use of intensity models
Andersen, Per Kragh , Houwelingen, Hans C. van , Cook, Richard J. , Joly, Pierre , Taylor, Jeremy M. G. , Abrahamowicz, Michał , Therneau, Terry M. , Kragh Andersen, Per , Pohar Perme, Maja , Cook, Richard J , Abrahamowicz, Michal , Martinussen, Torben

Mayo Clinic

Statistics in Medicine | October 11, 2020 | Volume: 40 | Issue: 1 | Pages: 185-211

10.1002/sim.8757 | PMID 33043497 Get It

Summary This paper provides guidance for researchers with some mathematical background on the conduct of time‐to‐event analysis in observational studies based on intensity (hazard) models. Discussions of basic concepts like time axis, event definition and censoring are given. Hazard models are introduced, with special emphasis on the Cox proportional hazards regression model. We provide check lists that may be useful both when fitting the model and assessing its goodness of fit and when interpreting the results. Special attention is paid to how to avoid problems with immortal time bias by introducing time‐dependent covariates. We discuss prediction based on hazard models and difficulties when attempting to draw proper causal conclusions from such models. Finally, we present a series of examples where the methods and check lists are exemplified. Computational details and implementation using the freely available R software are documented in Supplementary Material. The paper was prepared as part of the STRATOS initiative.
Transition from room temperature to cold‐stored platelets for the preservation of blood inventories during the COVID‐19 pandemic
Warner, Matthew A. , Kurian, Emil B., Hammel, Scott A., Buskirk, Camille M. van , Kor, Daryl J. , Stubbs, James R. , van Buskirk, Camille M, Warner, Matthew A

Mayo Clinic

Transfusion | October 8, 2020 | Volume: 61 | Issue: 1 | Pages: 72-77

10.1111/trf.16148 | PMID 33029791 Get It

AbstractBackgroundThe COVID‐19 pandemic has placed great strain on blood resources. In an effort to extend platelet (PLT) shelf life and minimize waste, our institution transitioned room temperature to cold‐stored PLTs for administration to bleeding patients.Study Design and MethodsWe describe the administrative and technical processes involved in transitioning room temperature PLTs to cold storage in April 2020. Additionally, we describe the clinical utilization of cold‐stored PLTs in the first month of this practice change, with a focus on changes in PLT counts after transfusion, hemostasis, and safety outcomes.ResultsA total of 61 cold‐stored PLT units were transfused to 40 bleeding patients, with a median (interquartile range [IQR]) of 1 (1‐2) units per patient. The median age was 68 (59‐73) years; 58% male. Median pretransfusion and posttransfusion PLTs counts were 88 (67‐109) and 115 (93‐145). A total of 95% of transfusions were administered in the operating room: 57% cardiac surgery, 20% vascular surgery, 8% general surgery, and 5% solid organ transplantation. Hemostasis was deemed to be adequate in all cases after transfusion. There were no transfusion reactions. One patient (3%) experienced a fever and infection within 5 days of transfusion, which was unrelated to transfusion. Median (IQR) hospital length of stay was 8.5 (6‐17) days. Two patients (5%) died in the hospital of complications not related to transfusion.ConclusionCold‐stored PLT utilization was associated with adequate hemostasis and no overt signal for patient harm. Conversion from room temperature to cold‐stored PLTs may be one method of reducing waste in times of scarce blood inventories.
Intelligence, educational attainment, and brain structure in those at familial high‐risk for schizophrenia or bipolar disorder
Zwarte, Sonja M. C. de , Brouwer, Rachel M. , Agartz, Ingrid , Alda, Martin , Alonso-Lana, Sílvia , Bearden, Carrie E. , Bonvino, Aurora , Bramon, Elvira , Buimer, Elizabeth E.L. , Canales‐Rodríguez, Erick J. , Cannon, Dara M. , Cannon, Tyrone D. , Caseras, Xavier , Chen, Qiang , Chung, Yoonho , Serna, Elena de la , Giorgio, Annabella Di , Eker, Çağdaş , Erk, Susanne , Fatjó‐Vilas, Mar , Fears, Scott C. , Foley, Sonya , Fullerton, Janice M. , Goghari, Vina M. , Goikolea, José Manuel , Goldman, Aaron L. , Gruber, Oliver , Hájek, Tomáš , Hawkins, Emma L. , Heinz, Andreas , Hıdıroğlu, Ceren , Hillegers, Manon H. J. , Houenou, Josselin , Pol, Hilleke E. Hulshoff , Hultman, Christina M., Johansson, Viktoria , Jönsson, Erik G. , Kane, Fergus , Kempton, Matthew J. , Kopeček, Miloslav , Krämer, Bernd , Lenroot, Rhoshel , Marcelis, Machteld , Mattay, Venkata S. , Meyer‐Lindenberg, Andreas , Mwangi, Benson , Nabulsi, Leila , Newport, Jason, Olman, Cheryl A. , Overs, Bronwyn J. , Özerdem, Ayşegül , Pergola, Giulio , Pomarol‐Clotet, Edith , Raduà, Joaquim , Ramsay, Ian S. , Roberts, Gloria , Salvador, Raymond , Sarıçiçek, Aybala , Sarró, Salvador , Simsek, Esma M., Şimşek, Fatma , Toulopoulou, Timothea , Vieta, Eduard , Walter, Henrik , Weinberger, Daniel R. , Whalley, Heather C. , Yalın, Nefize , Ching, Christopher R. K. , Thomopoulos, Sophia I. , Jahanshad, Neda , Thompson, Paul M. , Kahn, René S. , Haren, Neeltje E.M. van , de Zwarte, Sonja M C , Bramon, Elvira , Canales-Rodríguez, Erick J , Cannon, Tyrone D , Chung, Yoonho , Di Giorgio, Annabella , Doucet, Gaelle E , Eker, Mehmet Cagdas , Frangou, Sophia , Glahn, David C , Hajek, Tomas , Hulshoff Pol, Hilleke E , Johansson, Viktoria , Jönsson, Erik G , Koenis, Marinka M G , Kopecek, Miloslav , Krämer, Bernd , Michielse, Stijn , Pergola, Giulio , Pomarol-Clotet, Edith , Radua, Joaquim , Salvador, Raymond , Saricicek Aydogan, Aybala , Sarró, Salvador , Schofield, Peter R , Simsek, Fatma , Sponheim, Scott R , Sugranyes, Gisela , Vieta, E , Ching, Christopher R K , Thomopoulos, Sophia I , van Erp, Theo G M , Agartz, Ingrid , Buimer, Elizabeth E L , van Haren, Neeltje E M , Hillegers, Manon H J , Meyer-Lindenberg, Andreas , Walter, Henrik , Thompson, Paul M , Alda, Martin , Fullerton, Janice M , Ozerdem, Aysegul , Yalin, Nefize , Bertolino, Alessandro , Cahn, Wiepke , Castro‐Fornieles, Josefina , Bonnín, Caterina del Mar , Demro, Caroline , Frangou, Sophia , Gönül, Ali Saffet , Ingvar, Martin , Lawrie, Stephen M. , McDonald, Colm , Mitchell, Philip B , Moreno, Dolores Maria , Murray, Robin , Os, Jim van , Picchioni, Marco , Piguet, Camille , Richter, Anja , Schofield, Peter R. , Soares, Jair C. , Tronchin, Giulia , Wu, Mon‐Ju , Andreassen, Ole A.

Mayo Clinic

Human Brain Mapping | October 7, 2020 | Volume: 43 | Issue: 1 | Pages: 414-430

10.1002/hbm.25206 | PMID 33027543 Get It

AbstractFirst‐degree relatives of patients diagnosed with schizophrenia (SZ‐FDRs) show similar patterns of brain abnormalities and cognitive alterations to patients, albeit with smaller effect sizes. First‐degree relatives of patients diagnosed with bipolar disorder (BD‐FDRs) show divergent patterns; on average, intracranial volume is larger compared to controls, and findings on cognitive alterations in BD‐FDRs are inconsistent. Here, we performed a meta‐analysis of global and regional brain measures (cortical and subcortical), current IQ, and educational attainment in 5,795 individuals (1,103 SZ‐FDRs, 867 BD‐FDRs, 2,190 controls, 942 schizophrenia patients, 693 bipolar patients) from 36 schizophrenia and/or bipolar disorder family cohorts, with standardized methods. Compared to controls, SZ‐FDRs showed a pattern of widespread thinner cortex, while BD‐FDRs had widespread larger cortical surface area. IQ was lower in SZ‐FDRs (d = −0.42,p = 3 × 10−5), with weak evidence of IQ reductions among BD‐FDRs (d = −0.23,p = .045). Both relative groups had similar educational attainment compared to controls. When adjusting for IQ or educational attainment, the group‐effects on brain measures changed, albeit modestly. Changes were in the expected direction, with less pronounced brain abnormalities in SZ‐FDRs and more pronounced effects in BD‐FDRs. To conclude, SZ‐FDRs and BD‐FDRs show a differential pattern of structural brain abnormalities. In contrast, both had lower IQ scores and similar school achievements compared to controls. Given that brain differences between SZ‐FDRs and BD‐FDRs remain after adjusting for IQ or educational attainment, we suggest that differential brain developmental processes underlying predisposition for schizophrenia or bipolar disorder are likely independent of general cognitive impairment.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
Agathangelidis, Andreas , Chatzidimitriou, Anastasia , Gemenetzi, Katerina , Giudicelli, Véronique , Karypidou, Maria, Plevová, Karla , Davis, Zadie , Yan, Xiao‐Jie , Jeromin, Sabine , Schneider, Christof , Pedersen, Lone Bredo , Tschumper, Renee C. , Sutton, Lesley‐Ann, Gastel, Ellen J. van, Armand, Marine , Tausch, Eugen , Baer, Constance , Navarro, Alba , Septenville, Anne Langlois de, Guido, Valentina, Mitterbauer‐Hohendanner, Gerlinde, Brieghel, Christian , Lawless, Sarah, Meggendorfer, Manja , Brázdilová, Kamila, Ritgen, Matthias , Facco, Monica , Tresoldi, Cristina , Visentin, Andrea , Patriarca, Andrea , Catherwood, Mark , Bonello, Lisa, Sudarikov, Andrey , Roumelioti, Maria, Francová, Hana Skuhrová, Moysiadis, Theodoros , Giannopoulos, Krzysztof , Mansouri, Larry, Karan-Djurašević, Teodora , Sandaltzopoulos, Raphael , Fais, Franco , Kater, Arnon P. , Panovska, Irina, Rossi, Davide , Alshemmari, Salem , Costeas, Paul , Espinet, Blanca , Antić, Darko , Foroni, Letizia, Montillo, Marco , Trentin, Livio , Stavroyianni, Niki, Gaïdano, Gianluca , Celle, Paola Francia di, Niemann, Carsten Utoft , Anagnostopoulos, Αchilles , Pott, Christiane , Fischer, Kirsten , Hallek, Michael , Oscier, David , Jelinek, Diane F., Lefranc, Marie‐Paule , Belessi, Chrysoula, Davi, Frédéric , Rosenquist, Richard , Σταματόπουλος, Κώστας , Jelinek, Diane, Gaidano, Gianluca , Rosenquist, Richard , Espinet, Blanca , Baliakas, Panagiotis , Scarfò, Lydia , Biderman, Bella V. , Bagnara, Davide , Guido, Valentina, Dimovski, Aleksandar J , Vanura, Katrina , Veronese, Silvio , Bödör, Csaba , Panagiotidis, Panagiotis T. , Campo, Elı́as , Stilgenbauer, Stephan , Haferlach, Claudia , Chiorazzi, Nicholas , Pospı́šilová, Šárka , Kossida, Sofia , Langerak, Anton W. , Ghia, Paolo

Mayo Clinic

Blood | September 29, 2020 | Volume: 137 | Issue: 10 | Pages: 1365-1376

10.1182/blood.2020007039 | PMID 32992344 Get It

Abstract Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed “satellites,” were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.
Report of AAPM Task Group 235 Radiochromic Film Dosimetry: An Update to TG‐55
Niroomand‐Rad, Azam, Chiu‐Tsao, Sou‐Tung, Lewis, David F. , Soares, Christopher G., Battum, L.J. van, Trichter, Samuel , Kissick, M, Alvarez, P , Grams, Michael P. , Das, Indra J. , Massillon-JL, G. , Chan, Maria F.

Mayo Clinic

Medical Physics | September 29, 2020 | Volume: 47 | Issue: 12 | Pages: 5986-6025

10.1002/mp.14497 | PMID 32990328 Get It

The use of radiochromic film (RCF) dosimetry in radiation therapy is extensive due to its high level of achievable accuracy for a wide range of dose values and its suitability under a variety of measurement conditions. However, since the publication of the 1998 AAPM Task Group 55, Report No. 63 on RCF dosimetry, the chemistry, composition, and readout systems for RCFs have evolved steadily. There are several challenges in using the new RCFs, readout systems and validation of the results depending on their applications. Accurate RCF dosimetry requires understanding of RCF selection, handling and calibration methods, calibration curves, dose conversion methods, correction methodologies as well as selection, operation and quality assurance (QA) programs of the readout systems. Acquiring this level of knowledge is not straight forward, even for some experienced users. This Task Group report addresses these issues and provides a basic understanding of available RCF models, dosimetric characteristics and properties, advantages and limitations, configurations, and overall elemental compositions of the RCFs that have changed over the past 20 yr. In addition, this report provides specific guidelines for data processing and analysis schemes and correction methodologies for clinical applications in radiation therapy.
Population‐based analysis on the effect of nodal and distant metastases in sinonasal adenocarcinoma
Chweya, Cynthia M. , Low, Christopher M. , Abel, Kathryn M. Van , Stokken, Janalee K., Van Abel, Kathryn M , Gompel, Jamie J. Van , Choby, Garret

Mayo Clinic

Head & Neck | September 24, 2020 | Volume: 43 | Issue: 1 | Pages: 128-136

10.1002/hed.26457 | PMID 32929799 Get It

AbstractBackgroundMinimal information has been reported on the effect of distant and nodal metastases at the time of diagnosis on survival in patients with sinonasal adenocarcinoma (SNAC).MethodsThe Surveillance, Epidemiology, and End Results database was utilized to compare overall survival (OS) and disease‐specific survival (DSS).ResultsOf the 325 patients with SNAC identified, 5‐year and 10‐year OS for all included patients was 64% and 58%, respectively. On multivariate analysis, the presence of distant metastases (P < .0001), maxillary and frontal sinus primary tumors (P = .0042, P = .0006), and increasing age (P = .007) were risk factors for worsened DSS. The presence of regional spread to multiple cervical nodal basins (OS RR 3.26, P = .002; DSS RR 2.51, P = .013) and a single nodal basin (DSS RR 2.19, P = .046) was associated with worsened survival compared to no regional spread.ConclusionSurvival in SNAC was significantly worsened with increasing age, tumor site of origin, and distant metastatic disease.
Human papillomavirus oropharynx carcinoma: Aggressive de‐escalation of adjuvant therapy
Moore, Eric J. , Abel, Kathryn M. Van , Routman, David M. , Lohse, Christine M. , Price, Katharine A. , Neben-Wittich, M.A. , Kasperbauer, Jan L. , García, Joaquín J. , Hinni, Michael L., Patel, Samir H. , Janus, Jeffrey R. , Foote, Robert L. , J., Dan, Van Abel, Kathryn M , Price, Katharine A R, Neben-Wittich, Michelle, Ma, Dan J, Routman, David M , Chintakuntlawar, Ashish V. , Price, Daniel L.

Mayo Clinic

Head & Neck | September 24, 2020 | Volume: 43 | Issue: 1 | Pages: 229-237

10.1002/hed.26477 | PMID 32969095 Get It

AbstractBackgroundAggressive dose de‐escalated adjuvant radiation therapy (RT) in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC).MethodsPatients with HPV(+)OPSCC on a phase II clinical trial of primary surgery and neck dissection followed by dose de‐escalated RT (N = 79) were compared with a cohort of patients who received standard adjuvant therapy (N = 115). Local recurrence‐free, regional recurrence‐free, distant metastases‐free survival, and progression‐free survival (PFS) were assessed.ResultsOf 194 patients, 23 experienced progression at a median of 1.1 years following surgery (interquartile range [IQR] 0.7‐2.0; range 0.3‐5.4); 10 patients in the de‐escalated cohort and 13 patients in the standard cohort. The 3‐year PFS rate for the de‐escalated cohort was 87%, and in the standard cohort was 90% (hazard ratio [HR] 1.18, 95% confidence interval (CI) [0.50‐2.75]).ConclusionPatients with HPV(+)OPSCC who undergo surgical resection and neck dissection and meet criteria for adjuvant therapy can undergo aggressive dose de‐escalation of RT without increasing risk of progression locally, regionally or at distant sites.
Injectable conductive hydrogel restores conduction through ablated myocardium
Zyl, Martin van , Pedrotty, Dawn , Kuzmenko, Volodymyr , Sämfors, Sanna, Livia, Christopher , Vaidya, Vaibhav R. , Sugrue, Alan , Behfar, Atta , Asirvatham, Samuel J. , Gatenholm, Paul , Kapa, Suraj , van Zyl, Martin , Livia, Christopher , Vaidya, Vaibhav , Sugrue, Alan , Asirvatham, Samuel J , Gatenholm, Paul , Kapa, Suraj , Behfar, Atta , Karabulut, Erdem , McLeod, Christopher J.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 23, 2020 | Volume: 31 | Issue: 12 | Pages: 3293-3301

10.1111/jce.14762 | PMID 32966655 Get It

AbstractIntroductionTherapies for substrate‐related arrhythmias include ablation or drugs targeted at altering conductive properties or disruption of slow zones in heterogeneous myocardium. Conductive compounds such as carbon nanotubes may provide a novel personalizable therapy for arrhythmia treatment by allowing tissue homogenization.MethodsA nanocellulose carbon nanotube‐conductive hydrogel was developed to have conduction properties similar to normal myocardium. Ex vivo perfused canine hearts were studied. Electroanatomic activation mapping of the epicardial surface was performed at baseline, after radiofrequency ablation, and after uniform needle injections of the conductive hydrogel through the injured tissue. Gross histology was used to assess distribution of conductive hydrogel in the tissue.ResultsThe conductive hydrogel viscosity was optimized to decrease with increasing shear rate to allow expression through a syringe. The direct current conductivity under aqueous conduction was 4.3 × 10−1 S/cm. In four canine hearts, when compared with the homogeneous baseline conduction, isochronal maps demonstrated sequential myocardial activation with a shift in direction of activation to surround the edges of the ablated region. After injection of the conductive hydrogel, isochrones demonstrated conduction through the ablated tissue with activation restored through the ablated tissue. Gross specimen examination demonstrated retention of the hydrogel within the tissue.ConclusionsThis proof‐of‐concept study demonstrates that conductive hydrogel can be injected into acutely disrupted myocardium to restore conduction. Future experiments should focus on evaluating long‐term retention and biocompatibility of the hydrogel through in vivo experimentation.
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia
Hampel, Paul J. , Call, Timothy G. , Rabe, Kari G. , Leis, José F., Koehler, Amber B. , Fonder, Amie , Schwager, Susan M., Dyke, Daniel L. Van , Braggio, Esteban , Kenderian, Saad S. , Fonder, Amie L, Van Dyke, Daniel L, Chaffee, Kari G. , Braggio, Esteban , Ding, Wei , Muchtar, Eli , Wang, Yucai , Witzig, Thomas E. , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

The Oncologist | September 21, 2020 | Volume: 25 | Issue: 11 | Pages: 974-980

10.1634/theoncologist.2020-0388 | PMID 32886416 Get It

Abstract Background Approximately 25% of patients with chronic lymphocytic leukemia (CLL) experience a flare of disease following ibrutinib discontinuation. A critical question is whether this phenomenon may also occur when ibrutinib is temporarily held. This study aimed to determine the frequency and characteristics of disease flares in this setting and assess risk factors and clinical outcomes. Materials and Methods We identified all patients with CLL seen at Mayo Clinic between October 2012 and March 2019 who received ibrutinib. Temporary interruptions in treatment and associated clinical findings were ascertained. Results Among the 372 patients identified, 143 (38%) had at least one temporary interruption (median 1 hold, range 1–7 holds) in treatment. The median duration of interruption was 8 days (range 1–59 days) and the most common indication was periprocedural. Among the 143 patients with ≥1 hold, an associated disease flare was seen in 35 (25%) patients: mild (constitutional symptoms only) in 21 patients and severe (constitutional symptoms with exam/radiographic findings or laboratory changes) in 14 patients. Disease flare resolved with resuming ibrutinib in all patients. Predictive factors of disease flare included progressive disease at time of hold and ≥ 24 months of ibrutinib exposure. The occurrence of disease flare with an ibrutinib hold was associated with shorter event-free survival (hazard ratio 2.3; 95% confidence interval 1.3–4.1; p = .007) but not overall survival. Conclusion Temporary interruptions in ibrutinib treatment of patients with CLL are common, and one quarter of patients who held ibrutinib in this study experienced a disease flare. Resolution with resuming ibrutinib underscores the importance of awareness of this phenomenon for optimal management. Implications for Practice Ibrutinib is a very effective treatment for chronic lymphocytic leukemia (CLL) but needs to be taken continuously. Side effects, such as increased bleeding risk with procedures, require temporary interruptions in this continuous treatment. Rapid CLL progression following ibrutinib discontinuation has been increasingly recognized. This study demonstrates that similar flares in disease signs or symptoms may occur during ibrutinib holds as well. Importantly, management with restarting ibrutinib led to quick clinical improvement. Awareness of this phenomenon among clinicians is critical to avoid associated patient morbidity and premature cessation of effective treatment with ibrutinib if the flare is misidentified as true progression of disease.